Amneal Pharmaceuticals (AMRX) announced that the FDA has approved the company’s epinephrine injection USP, 1 mg/mL, in single-dose vials and 1 mg/mL multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals initiated with an Overweight at Barclays
- Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD
- Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise
- Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05%